157 related articles for article (PubMed ID: 35008437)
1. Characterization of GPVI- or GPVI-CD39-Coated Nanoparticles and Their Impact on In Vitro Thrombus Formation.
Nestele JA; Rohlfing AK; Dicenta V; Bild A; Eißler D; Emschermann F; Kremser M; Krutzke K; Schäffer TE; Borst O; Levi M; Korin N; Gawaz MP
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008437
[TBL] [Abstract][Full Text] [Related]
2. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
[TBL] [Abstract][Full Text] [Related]
3. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice.
Grüner S; Prostredna M; Koch M; Miura Y; Schulte V; Jung SM; Moroi M; Nieswandt B
Blood; 2005 Feb; 105(4):1492-9. PubMed ID: 15507524
[TBL] [Abstract][Full Text] [Related]
4. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet.
Chang CH; Chung CH; Tu YS; Tsai CC; Hsu CC; Peng HC; Tseng YJ; Huang TF
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377
[TBL] [Abstract][Full Text] [Related]
5. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo.
Massberg S; Konrad I; Bültmann A; Schulz C; Münch G; Peluso M; Lorenz M; Schneider S; Besta F; Müller I; Hu B; Langer H; Kremmer E; Rudelius M; Heinzmann U; Ungerer M; Gawaz M
FASEB J; 2004 Feb; 18(2):397-9. PubMed ID: 14656994
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin.
Ahmed MU; Kaneva V; Loyau S; Nechipurenko D; Receveur N; Le Bris M; Janus-Bell E; Didelot M; Rauch A; Susen S; Chakfé N; Lanza F; Gardiner EE; Andrews RK; Panteleev M; Gachet C; Jandrot-Perrus M; Mangin PH
Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2127-2142. PubMed ID: 32698684
[TBL] [Abstract][Full Text] [Related]
7. Implications of glycoprotein VI for theranostics.
Gawaz M; Vogel S; Pfannenberg C; Pichler B; Langer H; Bigalke B
Thromb Haemost; 2014 Jul; 112(1):26-31. PubMed ID: 24553806
[TBL] [Abstract][Full Text] [Related]
8. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
[TBL] [Abstract][Full Text] [Related]
9. Plant-based Food Cyanidin-3-Glucoside Modulates Human Platelet Glycoprotein VI Signaling and Inhibits Platelet Activation and Thrombus Formation.
Yao Y; Chen Y; Adili R; McKeown T; Chen P; Zhu G; Li D; Ling W; Ni H; Yang Y
J Nutr; 2017 Oct; 147(10):1917-1925. PubMed ID: 28855423
[No Abstract] [Full Text] [Related]
10. Dimeric Glycoprotein VI Binds to Collagen but Not to Fibrin.
Ebrahim M; Jamasbi J; Adler K; Megens RTA; M'Bengue Y; Blanchet X; Uhland K; Ungerer M; Brandl R; Weber C; Elia N; Lorenz R; Münch G; Siess W
Thromb Haemost; 2018 Feb; 118(2):351-361. PubMed ID: 29378359
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases.
Marcus AJ; Broekman MJ; Drosopoulos JH; Pinsky DJ; Islam N; Maliszewsk CR
Ital Heart J; 2001 Nov; 2(11):824-30. PubMed ID: 11770867
[TBL] [Abstract][Full Text] [Related]
12. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily.
Jandrot-Perrus M; Busfield S; Lagrue AH; Xiong X; Debili N; Chickering T; Le Couedic JP; Goodearl A; Dussault B; Fraser C; Vainchenker W; Villeval JL
Blood; 2000 Sep; 96(5):1798-807. PubMed ID: 10961879
[TBL] [Abstract][Full Text] [Related]
13. Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation.
Moraes LA; Spyridon M; Kaiser WJ; Jones CI; Sage T; Atherton RE; Gibbins JM
J Thromb Haemost; 2010 Mar; 8(3):577-87. PubMed ID: 20040043
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Inhibition of Glycoprotein VI- and Integrin α2β1-Induced Thrombus Formation Modulated by the Collagen Type.
Jooss NJ; Henskens YMC; Watson SP; Farndale RW; Gawaz MP; Jandrot-Perrus M; Poulter NS; Heemskerk JWM
Thromb Haemost; 2023 Jun; 123(6):597-612. PubMed ID: 36807826
[TBL] [Abstract][Full Text] [Related]
15. Differential Inhibition of Human Atherosclerotic Plaque-Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies: Functional and Imaging Studies.
Jamasbi J; Megens RT; Bianchini M; Münch G; Ungerer M; Faussner A; Sherman S; Walker A; Goyal P; Jung S; Brandl R; Weber C; Lorenz R; Farndale R; Elia N; Siess W
J Am Coll Cardiol; 2015 Jun; 65(22):2404-15. PubMed ID: 26046734
[TBL] [Abstract][Full Text] [Related]
16. Snake venom metalloproteinases, crotarhagin and alborhagin, induce ectodomain shedding of the platelet collagen receptor, glycoprotein VI.
Wijeyewickrema LC; Gardiner EE; Moroi M; Berndt MC; Andrews RK
Thromb Haemost; 2007 Dec; 98(6):1285-90. PubMed ID: 18064326
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel strategy to target CD39 antithrombotic activity to the endothelial-platelet microenvironment in kidney ischemia-reperfusion injury.
Sashindranath M; Dwyer KM; Dezfouli S; Selan C; Crikis S; Lu B; Yuan Y; Hickey MJ; Peter K; Robson SC; Cowan PJ; Nandurkar HH
Purinergic Signal; 2017 Jun; 13(2):259-265. PubMed ID: 28343356
[TBL] [Abstract][Full Text] [Related]
18. The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice.
Schönberger T; Ziegler M; Borst O; Konrad I; Nieswandt B; Massberg S; Ochmann C; Jürgens T; Seizer P; Langer H; Münch G; Ungerer M; Preissner KT; Elvers M; Gawaz M
Am J Physiol Cell Physiol; 2012 Oct; 303(7):C757-66. PubMed ID: 22814400
[TBL] [Abstract][Full Text] [Related]
19. From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks.
Martins Lima A; Martins Cavaco AC; Fraga-Silva RA; Eble JA; Stergiopulos N
Thromb Haemost; 2019 Nov; 119(11):1720-1739. PubMed ID: 31564053
[TBL] [Abstract][Full Text] [Related]
20. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?
Hohmann JD; Wang X; Krajewski S; Selan C; Haller CA; Straub A; Chaikof EL; Nandurkar HH; Hagemeyer CE; Peter K
Blood; 2013 Apr; 121(16):3067-75. PubMed ID: 23380744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
